PARP-1-IN-3 Secrets
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Most important trial targets have been To judge the security and tolerability of sifalimumab in dermatomyositis or pol